Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Sandip Patel, MD, is a board-certified medical oncologist who specializes in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancer. Dr. Patel is focused on developing personalized therapies that stimulate a patient’s immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types.
Lung Cancer Video Library 2020 - PATEL Emerging Molecular Targets in NSCLC EGFR Exon 20
dbrock
Lung Cancer Video Library 2020 - Emerging Molecular Targets in NSCLC EGFR Exon 20 with Dr. Sandip Patel
Image
For this new addition to the GRACE Lung Cancer Video Library, Dr. Sandip Patel joins GRACE to discuss current updates in non small cell lung cancer.
In this video, Dr. Patel discusses updated information on emerging molecular targets in nsclc - EGFR Exon 20.
To join the conversation, visit https://cancergrace.org/forum.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, Vernon Sondak, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and Fiorinda Muhaj, MD Anderson Cancer Center, discuss basal and squamous cell carcinoma, including diagnosis, treatment options, and skin cancer prevention.
To watch the complete playlist, click here.
Thanks to Regeneron and Daiichi-Sankyo.
Online Community
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Recent Comments
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: